A co-formulation of interferons alpha2b and gamma distinctively targets cell cycle in the glioblastoma-derived cell line U-87MG

BACKGROUND: HeberFERON is a co-formulation of α2b and γ interferons, based on their synergism, which has shown its clinical superiority over individual interferons in basal cell carcinomas. In glioblastoma (GBM), HeberFERON has displayed promising preclinical and clinical results. This led us to des...

Descripción completa

Detalles Bibliográficos
Autores principales: Miranda, Jamilet, Vázquez-Blomquist, Dania, Bringas, Ricardo, Fernandez-de-Cossio, Jorge, Palenzuela, Daniel, Novoa, Lidia I., Bello-Rivero, Iraldo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463508/
https://www.ncbi.nlm.nih.gov/pubmed/37644431
http://dx.doi.org/10.1186/s12885-023-11330-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463508/
https://www.ncbi.nlm.nih.gov/pubmed/37644431
http://dx.doi.org/10.1186/s12885-023-11330-2

Ejemplares similares